Abstract
IL-15, a promising cytokine for treating cancer and viral diseases, is presented in trans by the IL-15 receptor (IL-15R) alpha-chain to the IL-15Rβγc complex displayed on the surface of T cells and natural killer (NK) cells. We previously reported that an asparagine to aspartic acid substitution at amino acid 72 (N72D) of IL-15 provides a 4-5-fold increase in biological activity compared to the native molecule. In this report, we describe Chinese hamster ovary (CHO) cell expression of a soluble complex (IL-15 N72D:IL-15RαSu/Fc) consisting of the IL-15 N72D superagonist and a dimeric IL-15Rα sushi domain-IgG1 Fc fusion protein. A simple but readily scalable affinity and ion exchange chromatography method was developed to highly purify the complex having both IL-15 binding sites fully occupied. The immunostimulatory effects of this complex were confirmed using cell proliferation assays. Treatment of mice with a single intravenous dose of IL-15N72D:IL-15RαSu/Fc resulted in a significant increase in CD8+ T cells and NK cells that was not observed following IL-15 treatment. Pharmacokinetic analysis indicated that the complex has a 25-h half-life in mice which is considerably longer than <40-min half-life of IL-15. Thus, the enhanced activity of the IL-15N72D:IL-15RαSu/Fc complex is likely the result of the increased binding activity of IL-15N72D to IL-15Rβγc, optimized cytokine trans-presentation by the IL-15RαSu domain, the dimeric nature of the cytokine domain and its increased in vivo half-life compared to IL-15. These findings indicate that this IL-15 superagonist complex could serve as a superior immunostimulatory therapeutic agent.
MeSH Terms
Animals
Body Weight/drug effects
CHO Cells
Cell Separation
Chromatography, Gel
Cricetinae
Cricetulus
Electrophoresis, Polyacrylamide Gel
Humans
Interleukin-15/agonists,isolation & purification
Interleukin-15 Receptor alpha Subunit/agonists,isolation & purification
Lymphocytes/drug effects,metabolism
Male
Mammals/metabolism
Mice
Mice, Inbred C57BL
Mutant Proteins/metabolism
Organ Size/drug effects
Recombinant Fusion Proteins/genetics,metabolism,pharmacokinetics,pharmacology
Recombination, Genetic/genetics
Chemicals
Interleukin-15
Interleukin-15 Receptor alpha Subunit
Mutant Proteins
Recombinant Fusion Proteins
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Han Kai-ping
Altor BioScience Corporation, 2810 North Commerce Parkway, Miramar, FL 33025, USA.
Zhu Xiaoyun
Liu Bai
Jeng Emily
Kong Lin
Yovandich Jason L
Vyas Vinay V
Marcus Warren D
Chavaillaz Pierre-Andre
Romero Christian A
Rhode Peter R
Wong Hing C
References (20)
20 references, click to expand
-
Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.
J Immunol. 2006 Nov 1;177(9):6072-80
PMID: 17056533
-
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9166-71
PMID: 16757567
-
Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity.
J Biol Chem. 2008 Feb 15;283(7):4189-99
PMID: 18055460
-
The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha.
J Mol Biol. 2008 Sep 26;382(1):1-12
PMID: 18656487
-
Interleukin-2 and interleukin-15: immunotherapy for cancer.
Cytokine Growth Factor Rev. 2002 Apr;13(2):169-83
PMID: 11900992
-
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.
Nat Rev Immunol. 2006 Aug;6(8):595-601
PMID: 16868550
-
Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.
J Immunol. 2008 Feb 15;180(4):2099-106
PMID: 18250415
-
Novel human interleukin-15 agonists.
J Immunol. 2009 Sep 15;183(6):3598-607
PMID: 19710453
-
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo.
J Exp Med. 2009 Jan 16;206(1):25-34
PMID: 19103877
-
In vitro and in vivo characterization of a novel antibody-like single-chain TCR human IgG1 fusion protein.
J Immunol. 2005 Apr 1;174(7):4381-8
PMID: 15778403
-
Heterogeneity of monoclonal antibodies.
J Pharm Sci. 2008 Jul;97(7):2426-47
PMID: 17828757
-
High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer.
Mol Cancer Ther. 2009 Sep;8(9):2736-45
PMID: 19723883
-
Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis.
Annu Rev Immunol. 2006;24:657-79
PMID: 16551262
-
Interleukin-15:Interleukin-15 receptor α scaffold for creation of multivalent targeted immune molecules.
Protein Eng Des Sel. 2011 Apr;24(4):373-83
PMID: 21177283
-
Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins.
J Biol Chem. 2006 Jan 20;281(3):1612-9
PMID: 16284400
-
Twelve immunotherapy drugs that could cure cancers.
Immunol Rev. 2008 Apr;222:357-68
PMID: 18364014
-
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.
Hum Gene Ther. 2005 Apr;16(4):457-72
PMID: 15871677
-
Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion protein.
Clin Immunol. 2006 Oct;121(1):29-39
PMID: 16807113
-
E. coli expression and purification of human and cynomolgus IL-15.
Protein Expr Purif. 2009 Nov;68(1):42-8
PMID: 19435602
-
Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells.
Cancer Res. 2008 Apr 15;68(8):2972-83
PMID: 18413767